IISc re­searchers pro­pose a more ef­fec­tive treat­ment for tu­ber­cu­lo­sis

BioSpectrum (India) - - SCIENCE NEWS -

A team of re­searchers at the In­dian In­sti­tute of Sci­ence (IISc) has found whether and how drug re­sis­tance can de­velop against a can­di­date drug called Aug­mentin even be­fore the drug is ap­proved for treat­ing pa­tients with drug-re­sis­tant

TB. The re­searchers have found ways of over­com­ing this po­ten­tial re­sis­tance mech­a­nism, thereby mak­ing Aug­mentin a po­ten­tially pow­er­ful drug to treat both mul­tidrug-re­sis­tant TB (MDR-TB) and ex­ten­sively dru­gre­sis­tant TB (XDRTB). The team used in­te­grated ex­per­i­men­tal tech­nol­ogy and com­puter tools to un­der­stand the mech­a­nism by which re­sis­tance against Aug­mentin can set in. There are cer­tain an­tibi­otics such as clo­faz­imine that work by in­creas­ing the lev­els of re­ac­tive oxy­gen species (ROS) in­side bac­te­ria. The re­searchers are cur­rently test­ing if us­ing such an­tibi­otics along with Aug­mentin can ef­fi­ciently kill drug-re­sis­tant TB bac­te­ria. Aug­mentin and clo­faz­imine an­tibi­otics can to­gether el­e­vate the pro­duc­tion of ROS. The ex­ces­sive ROS in­side the bac­te­ria can then kill all forms of drug-re­sis­tant TB bac­te­ria.

Aug­mentin is cur­rently un­der­go­ing clin­i­cal tri­als in pa­tients with drug-re­sis­tant TB. It is al­ready be­ing used for com­mon bac­te­rial in­fec­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.